(Q40513418)

21 September 2017

title

Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation (English)

1 reference

invasive fungal infections

21 September 2017

main subject

fever of unknown origin

1 reference

based on heuristic

inferred from title

1 reference

R Trenschel

1

1 reference

21 September 2017

M Ditschkowski

2

1 reference

21 September 2017

A H Elmaagacli

3

1 reference

21 September 2017

M Koldehoff

4

1 reference

21 September 2017

H Ottinger

5

1 reference

21 September 2017

N Steckel

6

1 reference

21 September 2017

M Hlinka

7

1 reference

21 September 2017

R Peceny

8

1 reference

21 September 2017

P-M Rath

9

1 reference

21 September 2017

H Dermoumi

10

1 reference

21 September 2017

D W Beelen

11

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Bone Marrow Transplantation

21 September 2017

published in

1 reference

21 September 2017

volume

35

1 reference

21 September 2017

issue

6

1 reference

21 September 2017

page(s)

583-586

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704859

21 September 2017

exact match

0 references

cites work

The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

New drugs and novel targets for treatment of invasive fungal infections in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

Caspofungin: an echinocandin antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

Safety and tolerability of caspofungin acetate in the treatment of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

Lipopeptide inhibitors of fungal glucan synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704859

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.BMT.1704859

1 reference

Dimensions Publication ID

21 September 2017

1043383887

0 references

1 reference